Back to article: Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention

FIGURE 2: Sites of vulnerability on an HIV-1 envelope spike. BnAbs can be directed against several epitopes on gp120 including the CD4bs, the V1/V2 apex, the V3 glycan supersite site, and the silent face as well as epitopes on gp41 such as the gp41-gp120 interface region, the fusion peptide and the MPER. Examples of bnAbs targeting these sites are shown in Table 1.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.